Core Viewpoint - The company Bai'ao Saituo has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, leveraging its "Thousand Mice and Ten Thousand Antibodies" plan and RenMice human antibody platform, but faces multiple risks including reliance on cost-cutting for profitability, high proportion of related-party transactions, patent infringement lawsuits, and significant unremedied losses [1][4]. Group 1: Financial Performance and Cost Management - From 2022 to 2024, Bai'ao Saituo's operating revenue steadily increased, with net profit turning from a loss of 602 million yuan to a profit of 33.54 million yuan, and achieving a net profit of 114 million yuan in the first three quarters of this year [6]. - However, R&D expenses significantly decreased from 699 million yuan to 324 million yuan, and the total number of R&D personnel dropped from 627 to 337, with dedicated R&D staff reduced from 58 to 5 [6]. - The revenue growth of 446 million yuan during the same period contrasts with a decline in R&D expenses of 375 million yuan, raising concerns about whether profitability improvements stem from cost-cutting rather than genuine business growth [6]. Group 2: Related-Party Transactions and Patent Litigation - The antibody development business, a key growth area for Bai'ao Saituo, has a compound annual growth rate of 58.26% from 2022 to 2024, with a gross margin exceeding 80% [7]. - Nearly 30% of the revenue in this segment comes from related parties, specifically from joint ventures such as Doma Pharmaceutical and its subsidiary, contributing a total of 170 million yuan, which accounts for 27.43% of total antibody development revenue [7]. - The core technology platform RenMice faces intellectual property risks, as a lawsuit was filed by He Bo Pharmaceutical in September 2024, alleging patent infringement, which could undermine market confidence in the company's technological independence [7]. Group 3: Unremedied Losses and Debt Concerns - As of the end of 2024, Bai'ao Saituo has accumulated unremedied losses of 1.754 billion yuan, with the company acknowledging the risk of returning to losses if R&D investments remain high or revenue growth does not meet expectations [8]. - The controlling shareholders, Shen Yuele and his wife, face significant debt obligations, needing to repay approximately 129 million yuan from 2025 to 2028, primarily relying on the liquidation of their H-shares in the company [8]. - The total compensation for the company's directors, supervisors, and key technical personnel from 2022 to 2024 reached 61.6072 million yuan, maintaining a high level despite the company's losses, which has raised inquiries from the stock exchange [8].
百奥赛图科创板上市背后的三大隐忧：盈利真实性、关联交易与巨额亏损待解